The Motley Fool · Jan 13, 2023
Why These Two Biotech Stocks Blasted Higher This Week
There's nothing like a big-premium buyout to send a company's share price to the moon.
CI
NASDAQ · CINC
CinCor Pharma, Inc.
Healthcare · Biotechnology
$29.06
Up+$0.00 (+0.00%)
Updated Sep 14, 2026, 12:55 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.27B
- P/E ratio
- -20.44
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 0
- Avg. volume
- 619.3K
Price performance
CINC price history
1M range · 0 trading sessions · Daily adjusted prices
CINC does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest CINC news
The latest Smart Investors Daily articles mentioning CINC.
Stock researchCompany · Overview
CINC research
Overview
Company profile and research snapshot.
Company profile
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $48.50
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 12, 2023 | Barclays | Equal-Weight | — |
| Jan 10, 2023 | Morgan Stanley | Equal-Weight | — |
| Dec 8, 2022 | Barclays | Overweight | — |
| Dec 7, 2022 | Barclays | Overweight | — |
| Nov 29, 2022 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Benzinga · Jan 12, 2023
Where CinCor Pharma Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on CinCor Pharma (NASDAQ:CINC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 2 1 0 0 3M Ago 1 0 0 0 0 These 6 analysts have an average price target of $32.33 versus the current price of CinCor Pharma at $28.75, implying upside. Below is a summary of how these 6 analysts rated CinCor ...Full story available on Benzinga.com
Zacks Investment Research · Jan 11, 2023
Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More
Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.
Zacks Investment Research · Jan 10, 2023
AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B
AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
